Article Text

other Versions

Download PDFPDF
Response to: ‘Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?’ by Cantini and Benucci
  1. Marc Scherlinger,
  2. Thierry Schaeverbeke
  1. Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
  1. Correspondence to Dr Marc Scherlinger, Department of Rheumatology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux 33076, France; marc.scherlinger{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

In their correspondence, Cantini and Benucci1 express their concern about the lack of real-life data supporting the switch from originator to biosimilar biological disease-modifying antirheumatic drugs, as recommended in the recently issued consensus-based recommendations.2 They argue that the Danish Nationwide Biologic (DANBIO) registry reporting real-life data showed a lower than expected retention rate after the switch to biosimilar infliximab (bio-IFX) and etanercept.3 4

Concerning bio-IFX, several other real-life studies have been published so far. One Dutch and one French open studies have examined real-life outcomes of the switch from originator to bio-IFX in patients with inflammatory rheumatic diseases.5 6 Both …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles